The global short-acting insulin market size was valued at USD 10.02 billion in 2025 and is projected to grow from USD 10.22 billion in 2026 to USD 11.97 billion by 2034, registering a CAGR of 2% during the forecast period from 2026 to 2034. North America dominated the short-acting insulin market with a market share of 41.2% in 2025.
Short-acting insulin is a type of insulin medication that helps control blood glucose levels after meals by increasing the uptake of glucose into cells and reducing glucose production by the liver. It typically begins working within 30–60 minutes after administration and has a longer duration of action than rapid-acting insulin. Short-acting insulin is commonly used as part of diabetes management to control mealtime blood sugar levels and maintain overall glucose balance.
Download a Free Sample To learn more about this report,
Expanding Availability of Biosimilar Short-Acting Insulin
The development and commercialization of biosimilar short-acting insulin is emerging as an important trend in the market as healthcare providers and patients increasingly seek affordable alternatives to established insulin products. Biosimilar insulin can increase competition among manufacturers, expand treatment options, and potentially reduce the cost burden associated with diabetes management. This trend is particularly important in markets where insulin affordability and access remain major concerns. Manufacturers are also investing in regulatory approvals and commercial launches to strengthen their presence in the insulin market, while healthcare systems are increasingly considering biosimilars as part of cost-effective treatment strategies. The expansion of biosimilar options is expected to support broader access to short-acting insulin and intensify competition among established and emerging pharmaceutical companies. The FDA has noted that biosimilar approvals can increase medication options and potentially lower healthcare costs.
Integration of Smart Technology With Insulin Delivery
The integration of smart technology, connected insulin pens, continuous glucose monitoring (CGM), and digital diabetes applications is changing how patients administer and monitor short-acting insulin. Connected delivery devices can record insulin doses, injection timing, and other treatment information, allowing patients and healthcare professionals to better understand insulin use alongside glucose readings. These technologies can help reduce missed or repeated doses, support treatment adherence, and enable more personalized diabetes management. The growing connection between insulin delivery devices and digital health platforms is also supporting a shift toward data-driven diabetes care, where treatment decisions can be informed by continuously collected patient information. As digital diabetes ecosystems become more sophisticated, pharmaceutical and medical device companies are increasingly focusing on solutions that combine insulin delivery with monitoring and data management capabilities.
Government Initiatives and Improved Insulin Accessibility Support Market Expansion
Government initiatives aimed at preventing diabetes, improving treatment access, and reducing the financial burden of insulin therapy are supporting the growth of the short-acting insulin market. Public healthcare programs, insurance coverage, pricing reforms, and diabetes management initiatives are helping more patients obtain essential insulin treatments. This is particularly important because people with Type 1 diabetes require insulin for survival, while many patients with Type 2 diabetes also require insulin as the disease progresses. Governments are increasingly focusing on affordable diabetes care as the global prevalence of diabetes continues to rise. Expanded reimbursement programs and policies designed to improve insulin affordability can increase treatment access and support demand for short-acting insulin products.
In September 2025, Sanofi: The company announced that it would cap the monthly cost of all its insulin products at USD 35 for U.S. patients beginning January 2026, expanding its affordability program to patients regardless of insurance status and supporting broader access to insulin therapy.
High Insulin Prices and Treatment Costs Limit Patient Access
The high cost of insulin therapy remains a significant restraint for the short-acting insulin market, particularly for patients who require regular or lifelong treatment. Although short-acting insulin is essential for controlling blood glucose levels around meals, the overall cost of insulin products can place a considerable financial burden on patients, especially those without adequate insurance coverage. The complexity of insulin manufacturing, strict regulatory requirements, limited competition in some markets, and costs associated with research, production, distribution, and healthcare services can contribute to elevated prices. High out-of-pocket expenses may also encourage patients to delay prescriptions, reduce doses, or switch to less expensive treatment options, creating barriers to consistent insulin use.
In July 2025, Novo Nordisk: The company expanded its insulin affordability efforts in the U.S. through NovoCare patient-support resources, including coverage assistance and savings programs, highlighting continued industry efforts to address the financial burden associated with insulin therapy.
Advances in Biosimilar Insulin Development Create New Growth Opportunities
The development of biosimilar and interchangeable short-acting insulin products presents a significant opportunity for market expansion by increasing competition and improving affordability. Traditional insulin markets have been dominated by a limited number of major pharmaceutical companies, creating opportunities for new manufacturers to enter as patents expire and regulatory pathways become clearer. Biosimilars can provide healthcare providers and patients with additional treatment options while potentially reducing treatment costs. Advances in biotechnology, manufacturing processes, regulatory frameworks, and clinical development are making it increasingly feasible for pharmaceutical companies to develop alternative insulin products. Greater availability of biosimilar short-acting insulin could also improve access in emerging markets where treatment affordability remains a major concern.
In July 2025, Biocon Biologics: The company received U.S. FDA approval for Kirsty (insulin aspart-xjhz), the first rapid-acting interchangeable biosimilar to Novolog, providing an additional short-acting insulin option and strengthening competition in the U.S. insulin market.
Complex Manufacturing and Regulatory Requirements Restrict New Market Entrants
The development of short-acting insulin presents significant challenges because insulin is a complex biological product requiring advanced manufacturing capabilities, extensive quality controls, and rigorous regulatory evaluation. New manufacturers must invest heavily in research, manufacturing infrastructure, clinical development, regulatory compliance, and distribution before bringing competing products to market. These requirements can make it difficult for smaller pharmaceutical companies to compete with established manufacturers that already possess large-scale production facilities, extensive supply networks, strong brands, and regulatory expertise. In addition, maintaining consistent product quality and ensuring reliable cold-chain distribution adds further complexity, particularly when companies seek to expand into developing and geographically diverse markets.
Based on drug, the market is segmented into Novolog, Humalog, and Humulin. The Novolog segment dominated the Short-Acting Insulin market in 2025, accounting for 39.5% of the market share. Novolog, also known as insulin aspart, is a rapid-acting insulin widely used to control blood glucose levels around mealtimes. Its established clinical use, broad availability, and adoption across different patient groups have supported its leading position in the market. Humalog and Humulin also maintain significant market presence due to their established use in diabetes management and availability across multiple healthcare markets.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
North America dominated the Short-Acting Insulin market, accounting for 41.2% of the global market in 2025, with a market value of USD 4.13 billion. The regional market is projected to grow at a CAGR of 5.31%. Growth is supported by the high prevalence of diabetes, established healthcare infrastructure, strong adoption of insulin analogs, and broad availability of advanced insulin delivery systems. The region also benefits from extensive insurance coverage and continued efforts to improve insulin affordability and access.
The United States represents the largest market within North America, supported by its large diagnosed diabetes population, high insulin utilization, advanced healthcare infrastructure, and widespread availability of short-acting insulin products. The market is further supported by the adoption of insulin pens, connected delivery technologies, and improvements in diabetes management.
Canada's Short-Acting Insulin market is supported by a well-developed healthcare system, established diabetes management programs, and government-supported access to essential medicines. The growing diabetes burden and continued use of insulin analogs are supporting demand for short-acting insulin. Increasing attention to insulin affordability and provincial reimbursement programs is also influencing market access.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 28.6% of the Short-Acting Insulin market in 2025, generating USD 2.87 billion in revenue. The regional market is expected to expand at a CAGR of 5.12%. Growth is supported by established healthcare systems, high levels of diabetes diagnosis and treatment, favorable reimbursement structures, and increasing availability of insulin biosimilars.
Germany is a major European market for short-acting insulin, supported by its comprehensive healthcare system, high healthcare expenditure, and established diabetes treatment infrastructure. Demand is driven by the large population requiring glucose-lowering therapies and the widespread availability of insulin analogs. The country's emphasis on evidence-based treatment and reimbursement also supports continued use of short-acting insulin products.
The United Kingdom Short-Acting Insulin market benefits from the country's universal healthcare system and structured diabetes management through the National Health Service. Increasing diabetes prevalence, established clinical guidelines, and access to insulin therapies support market demand. The growing focus on cost-effective prescribing and the availability of biosimilar products are also shaping the market.
Asia Pacific accounted for 21.4% of the Short-Acting Insulin market in 2025, with a market value of USD 2.14 billion. The region is projected to register the highest CAGR among the major regions at 7.24%. Growth is driven by the rising prevalence of diabetes, expanding healthcare infrastructure, increasing awareness of diabetes management, and improving access to insulin therapies.
Japan represents an established short-acting insulin market supported by its advanced healthcare infrastructure, aging population, and high standards of diabetes management. Demand is supported by the continued use of insulin analogs, increasing adoption of convenient insulin delivery devices, and the country's emphasis on managing chronic diseases.
China's Short-Acting Insulin market is supported by its large diabetes population, expanding healthcare infrastructure, and growing access to diabetes treatment. Domestic pharmaceutical manufacturing and government-led procurement initiatives are also influencing the competitive environment and improving the availability of insulin products.
Latin America accounted for 5.1% of the Short-Acting Insulin market in 2025, representing a market value of USD 0.51 billion. The regional market is expected to grow at a CAGR of 5.67%. Rising diabetes prevalence, improving healthcare access, increasing awareness of disease management, and government efforts to expand essential medicine availability are supporting market growth.
Brazil represents a major short-acting insulin market in Latin America, supported by its large population, growing diabetes burden, and extensive public and private healthcare networks. Government-supported healthcare programs and public procurement of essential medicines play an important role in improving insulin accessibility. Increasing diabetes diagnosis and treatment, combined with improvements in healthcare infrastructure, is expected to sustain demand for short-acting insulin products.
The Middle East and Africa accounted for 3.7% of the Short-Acting Insulin market in 2025, with a market value of USD 0.37 billion. The regional market is projected to grow at a CAGR of 5.48%. Growth is driven by the increasing prevalence of diabetes, improving healthcare infrastructure, rising healthcare expenditure, and greater awareness of diabetes diagnosis and treatment. In the Middle East, investments in advanced healthcare facilities and chronic disease management are improving access to insulin therapies.
The UAE market is supported by a high prevalence of diabetes, strong healthcare infrastructure, and substantial investment in chronic disease management. Government initiatives focused on improving diabetes prevention and treatment are increasing awareness and access to modern therapies. The country's advanced hospital and pharmacy networks also support the availability of short-acting insulin products and modern delivery devices.
The Short-Acting Insulin market is highly consolidated, with major pharmaceutical companies competing through established insulin brands, manufacturing capabilities, global distribution networks, affordability initiatives, and improvements in insulin delivery. Novo Nordisk, Sanofi, and Eli Lilly and Company remain among the leading participants, while companies such as Verily and Sensile are contributing through digital diabetes management and connected insulin-delivery technologies. Competition is increasingly focused on improving patient access, developing convenient delivery formats, and integrating insulin therapy with digital health solutions.
Eli Lilly and Company is a major participant in the Short-Acting Insulin market, with Humalog (insulin lispro) serving as one of its key mealtime insulin products. The company's portfolio includes Humalog U-100, Humalog U-200, Humalog Junior KwikPen, and other insulin lispro formulations, providing multiple options for patients with diabetes. Lilly is also expanding access through lower-priced, non-branded insulin lispro products, while its KwikPen platform provides convenient prefilled delivery options. In 2026, Lilly continued to offer Humalog and insulin lispro through its KwikPen and other formulations, although the company announced the discontinuation of certain vial presentations in selected markets, reflecting ongoing portfolio optimization and changes in insulin delivery preferences.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com